About CytomX Therapeutics (NASDAQ:CTMX)
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Bristol-Myers Squibb Company, ImmunoGen, Inc., MD Anderson, and Pfizer Inc. to develop Probody therapeutics. It also has a strategic collaboration with Amgen, Inc. to develop T cell-bispecific probody therapeutic targeting epidermal growth factor receptor-CD3. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CTMX
CUSIPN/A
Phone650-515-3185
Debt
Debt-to-Equity RatioN/A
Current Ratio6.36%
Quick Ratio6.36%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$71.62 million
Price / Sales14.37
Cash FlowN/A
Price / CashN/A
Book Value$1.82 per share
Price / Book14.65
Profitability
EPS (Most Recent Fiscal Year)($1.16)
Net Income$-43,090,000.00
Net Margins-60.17%
Return on Equity-71.42%
Return on Assets-13.12%
Miscellaneous
Employees93
Outstanding Shares38,610,000
CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions
What is CytomX Therapeutics' stock symbol?
CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."
How were CytomX Therapeutics' earnings last quarter?
CytomX Therapeutics (NASDAQ:CTMX) released its quarterly earnings results on Wednesday, March, 7th. The biotechnology company reported $0.02 earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.43) by $0.45. The biotechnology company earned $27.07 million during the quarter, compared to analysts' expectations of $10.70 million. CytomX Therapeutics had a negative return on equity of 71.42% and a negative net margin of 60.17%. View CytomX Therapeutics' Earnings History.
When is CytomX Therapeutics' next earnings date?
What price target have analysts set for CTMX?
10 brokerages have issued twelve-month target prices for CytomX Therapeutics' stock. Their forecasts range from $37.00 to $44.00. On average, they expect CytomX Therapeutics' stock price to reach $40.1667 in the next twelve months. View Analyst Ratings for CytomX Therapeutics.
What are Wall Street analysts saying about CytomX Therapeutics stock?
Here are some recent quotes from research analysts about CytomX Therapeutics stock:
- 1. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (3/12/2018)
- 2. Cann analysts commented, "Loss per share was $0.69, compared to our estimate of $0.56. This was the result of higher than expected R&D expense of $28.1 million compared to our estimate of $15.2 million, which resulted from a $10 million payment to UCSB for a sublicense payment. This was partially offset by higher than estimated revenue of $8.8 million compared to our estimated $1.0 million." (8/8/2017)
- 3. Cowen Inc analysts commented, "CTMX announced that the first patient in CX-2009’s (CD166 PDC) Phase I trial has." (6/28/2017)
- 4. HC Wainwright analysts commented, "Before the market opened on May 5, TG reported 1Q17 results. The company recently reported preliminary data from its ongoing Phase II study of TG-1101 in patients with relapsing forms of multiple sclerosis. Preliminary results indicated that TG-1101 was well tolerated with no Grade III/IV adverse events (AEs) observed and the most commonly reported AE being infusion-related reactions, with median time on study of five months. All patients achieved the primary endpoint of greater than 95% B-cell depletion by four weeks. The median B-cell depletion at week four was reported to be 99% after two infusions with a cumulative dose of 600 mg, which compares favorably to other anti-CD20 monoclonal antibodies (mAbs). Management indicated that additional data from the ongoing Phase II study will be reported later this year and that the company is on track to initiate a Phase III trial in MS in 2H17." (5/8/2017)
Who are some of CytomX Therapeutics' key competitors?
Some companies that are related to CytomX Therapeutics include Intercept Pharmaceuticals (ICPT), Corcept Therapeutics (CORT), Spectrum Pharmaceuticals (SPPI), Esperion Therapeutics (ESPR), Arena Pharmaceuticals (ARNA), Aimmune Therapeutics (AIMT), Insmed (INSM), Cambrex (CBM), OPKO Health (OPK), MyoKardia (MYOK), Phibro Animal Health (PAHC), Madrigal Pharmaceuticals (MDGL), Enanta Pharmaceuticals (ENTA), Prestige Brands (PBH), Xencor (XNCR), Innoviva (INVA), Akcea Therapeutics (AKCA) and Radius Health (RDUS).
Who are CytomX Therapeutics' key executives?
CytomX Therapeutics' management team includes the folowing people:
- Dr. Sean A. McCarthy, Pres, CEO & Director (Age 51)
- Mr. Frederick W. Gluck, Co-Founder & Director (Age 83)
- Dr. W. Michael Kavanaugh M.D., Chief Scientific Officer and Head of Research & Non-Clinical Devel. (Age 62)
- Dr. Rachel Wallach Humphrey M.D., Ph.D., Chief Medical Officer (Age 57)
- Prof. Patrick S. Daugherty Ph.D., Founder and Member of Scientific Advisory Board
Has CytomX Therapeutics been receiving favorable news coverage?
News stories about CTMX stock have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. CytomX Therapeutics earned a news sentiment score of 0.04 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 45.65 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of CytomX Therapeutics?
Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CytomX Therapeutics' stock price today?
One share of CTMX stock can currently be purchased for approximately $26.66.
How big of a company is CytomX Therapeutics?
CytomX Therapeutics has a market capitalization of $1.07 billion and generates $71.62 million in revenue each year. The biotechnology company earns $-43,090,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. CytomX Therapeutics employs 93 workers across the globe.
How can I contact CytomX Therapeutics?
CytomX Therapeutics' mailing address is 151 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected]
MarketBeat Community Rating for CytomX Therapeutics (CTMX)
MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote "Outperform" if you believe CTMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
CytomX Therapeutics (NASDAQ:CTMX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
10 Wall Street analysts have issued ratings and price targets for CytomX Therapeutics in the last 12 months. Their average twelve-month price target is $40.1667, suggesting that the stock has a possible upside of 50.66%. The high price target for CTMX is $44.00 and the low price target for CTMX is $37.00. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.80 | 2.80 | 2.64 | 2.56 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $40.1667 | $37.8571 | $33.8750 | $32.6667 |
| Price Target Upside: | 50.66% upside | 11.34% upside | 48.12% upside | 41.48% upside |
CytomX Therapeutics (NASDAQ:CTMX) Consensus Price Target History
CytomX Therapeutics (NASDAQ:CTMX) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
CytomX Therapeutics (NASDAQ:CTMX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
CytomX Therapeutics (NASDAQ CTMX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.70%
Institutional Ownership Percentage: 78.07%
CytomX Therapeutics (NASDAQ CTMX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/2/2018 | Debanjan Ray | CFO | Sell | 3,000 | $28.12 | $84,360.00 | 7,741 |  |
| 3/26/2018 | Frederick W Gluck | Director | Sell | 5,000 | $31.93 | $159,650.00 | | |
| 3/2/2018 | Debanjan Ray | CFO | Sell | 33,000 | $29.99 | $989,670.00 | | |
| 3/2/2018 | Frederick W Gluck | Director | Sell | 16,181 | $30.00 | $485,430.00 | | |
| 3/2/2018 | Rachel Humphrey | Insider | Sell | 16,160 | $30.00 | $484,800.00 | 46,394 | |
| 2/28/2018 | Frederick W Gluck | Director | Sell | 3,819 | $30.00 | $114,570.00 | | |
| 2/28/2018 | Rachel Humphrey | Insider | Sell | 23,840 | $30.00 | $715,200.00 | 54,074 | |
| 2/1/2018 | Debanjan Ray | CFO | Sell | 2,548 | $26.69 | $68,006.12 | 4,741 | |
| 1/5/2018 | Frederick W Gluck | Director | Sell | 10,000 | $25.01 | $250,100.00 | | |
| 1/5/2018 | Sean A Mccarthy | Insider | Sell | 6,526 | $25.01 | $163,215.26 | 11,169 | |
| 1/2/2018 | Debanjan Ray | CFO | Sell | 2,500 | $21.11 | $52,775.00 | | |
| 1/2/2018 | Sean A Mccarthy | Insider | Sell | 13,052 | $21.04 | $274,614.08 | 17,695 | |
| 12/26/2017 | Frederick W Gluck | Director | Sell | 5,000 | $22.29 | $111,450.00 | | |
| 12/1/2017 | Debanjan Ray | CFO | Sell | 2,500 | $20.58 | $51,450.00 | | |
| 12/1/2017 | Sean A Mccarthy | Insider | Sell | 14,340 | $20.60 | $295,404.00 | | |
| 11/1/2017 | Debanjan Ray | CFO | Sell | 2,500 | $20.00 | $50,000.00 | 12,126 | |
| 11/1/2017 | Sean A Mccarthy | CEO | Sell | 14,342 | $19.86 | $284,832.12 | 18,587 | |
| 10/4/2017 | Frederick W Gluck | Director | Sell | 10,000 | $24.27 | $242,700.00 | | |
| 10/4/2017 | Robert I Tepper | Major Shareholder | Sell | 24,777 | $24.34 | $603,072.18 | | |
| 10/4/2017 | Sean A Mccarthy | CEO | Sell | 19,120 | $24.13 | $461,365.60 | 23,365 | |
| 10/4/2017 | William Michael Kavanaugh | Insider | Sell | 48,368 | $24.34 | $1,177,277.12 | | |
| 10/2/2017 | Debanjan Ray | CFO | Sell | 2,500 | $18.10 | $45,250.00 | | |
| 10/2/2017 | Sean A Mccarthy | Insider | Sell | 9,562 | $18.57 | $177,566.34 | | |
| 9/26/2017 | Frederick W Gluck | Director | Sell | 5,000 | $17.30 | $86,500.00 | | |
| 9/19/2017 | Robert I Tepper | Major Shareholder | Sell | 20,000 | $18.00 | $360,000.00 | 54,293 | |
| 9/1/2017 | Debanjan Ray | CFO | Sell | 2,500 | $17.17 | $42,925.00 | 17,126 | |
| 9/1/2017 | Sean A Mccarthy | Insider | Sell | 9,930 | $17.32 | $171,987.60 | 14,175 | |
| 8/31/2017 | Sean A Mccarthy | Insider | Sell | 18,756 | $17.50 | $328,230.00 | 23,001 | |
| 8/9/2017 | Debanjan Ray | CFO | Sell | 2,500 | $15.00 | $37,500.00 | 19,626 | |
| 8/9/2017 | Sean A Mccarthy | Insider | Sell | 4,781 | $15.00 | $71,715.00 | 9,026 | |
| 7/3/2017 | Debanjan Ray | CFO | Sell | 2,500 | $15.47 | $38,675.00 | 22,126 | |
| 7/3/2017 | Sean A Mccarthy | Insider | Sell | 4,781 | $15.52 | $74,201.12 | 9,026 | |
| 6/29/2017 | Robert I Tepper | Major Shareholder | Sell | 15,000 | $16.00 | $240,000.00 | 44,777 | |
| 6/26/2017 | Frederick W Gluck | Director | Sell | 5,000 | $14.61 | $73,050.00 | | |
| 6/26/2017 | Sean A Mccarthy | Insider | Sell | 4,481 | $15.00 | $67,215.00 | 8,726 | |
| 6/5/2017 | Sean A Mccarthy | Insider | Sell | 300 | $15.00 | $4,500.00 | 4,545 | |
| 5/1/2017 | Sean A Mccarthy | Insider | Sell | 4,781 | $15.70 | $75,061.70 | 6,760 | |
| 4/12/2017 | Kevin P Starr | Major Shareholder | Sell | 28,357 | $16.36 | $463,920.52 | 31,419 | |
| 4/4/2017 | Sean A Mccarthy | Insider | Sell | 9,562 | $17.22 | $164,657.64 | 6,760 | |
| 3/27/2017 | Rock Ventures Lp Third | Major Shareholder | Sell | 1,650,000 | $17.39 | $28,693,500.00 | | |
| 3/20/2017 | Robert C Goeltz II | CFO | Sell | 21,517 | $19.81 | $426,251.77 | 31,306 | |
| 3/20/2017 | Sean A Mccarthy | Insider | Sell | 14,343 | $19.60 | $281,122.80 | 16,322 | |
| 3/3/2017 | Sean A Mccarthy | Insider | Sell | 14,343 | $15.00 | $215,145.00 | 16,322 | |
| 11/28/2016 | Ix L.P. Canaan | Director | Sell | 38,459 | $11.56 | $444,586.04 | | |
| 11/22/2016 | Ix L.P. Canaan | Director | Sell | 42,550 | $11.71 | $498,260.50 | | |
| 11/21/2016 | Ix L.P. Canaan | Director | Sell | 45,324 | $11.61 | $526,211.64 | | |
| 11/16/2016 | Ix L.P. Canaan | Director | Sell | 51,581 | $11.50 | $593,181.50 | | |
| 11/15/2016 | Timothy M Shannon | Director | Sell | 33,064 | $11.48 | $379,574.72 | 268 | |
| 11/14/2016 | Ix L.P. Canaan | Director | Sell | 86,270 | $11.16 | $962,773.20 | | |
| 11/9/2016 | Ix L.P. Canaan | Director | Sell | 13,730 | $11.03 | $151,441.90 | | |
| 6/10/2016 | Timothy M Shannon | Director | Sell | 48,427 | $10.07 | $487,659.89 | 134 | |
| 6/7/2016 | Ix L.P. Canaan | Director | Sell | 111,498 | $10.01 | $1,116,094.98 | | |
| 6/3/2016 | Ix L.P. Canaan | Director | Sell | 59,621 | $10.80 | $643,906.80 | | |
| 6/1/2016 | Ix L.P. Canaan | Director | Sell | 22,463 | $10.75 | $241,477.25 | | |
| 5/27/2016 | Ix L.P. Canaan | Director | Sell | 25,082 | $10.60 | $265,869.20 | | |
| 5/26/2016 | Timothy M Shannon | Director | Sell | 51,343 | $10.34 | $530,886.62 | 134 | |
| 5/24/2016 | Ix L.P. Canaan | Director | Sell | 13,253 | $10.09 | $133,722.77 | | |
| 5/20/2016 | Ix L.P. Canaan | Director | Sell | 8,687 | $10.10 | $87,738.70 | | |
| 10/14/2015 | Cynthia J Ladd | VP | Buy | 3,000 | $12.00 | $36,000.00 | 3,000 | |
| 10/14/2015 | Frederick W Gluck | Director | Buy | 15,000 | $12.00 | $180,000.00 | 147,791 | |
| 10/14/2015 | James E Flynn | Insider | Buy | 625,000 | $12.00 | $7,500,000.00 | | |
(Data available from 1/1/2013 forward)
CytomX Therapeutics (NASDAQ CTMX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | CytomX Therapeutics (CTMX) Cut to Hold at BidaskClub
www.americanbankingnews.com - April 18 at 10:05 AM |
| BidaskClub Downgrades CytomX Therapeutics (CTMX) to Sell
www.americanbankingnews.com - April 16 at 8:40 PM |
| CytomX Therapeutics (CTMX) Expected to Post Quarterly Sales of $19.77 Million
www.americanbankingnews.com - April 15 at 2:14 AM |
| Zacks: Analysts Anticipate CytomX Therapeutics Inc (CTMX) to Announce -$0.30 Earnings Per Share
www.americanbankingnews.com - April 13 at 9:19 PM |
| CytomX Therapeutics Inc (CTMX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - April 12 at 5:43 PM |
| CytomX Therapeutics (CTMX) Upgraded to "Hold" at BidaskClub
www.americanbankingnews.com - April 11 at 10:10 PM |
| Insider Selling: CytomX Therapeutics Inc (CTMX) CFO Sells 3,000 Shares of Stock
www.americanbankingnews.com - April 4 at 4:16 PM |
| CytomX Therapeutics (CTMX) Lifted to Hold at ValuEngine
www.americanbankingnews.com - April 3 at 5:16 PM |
| CytomX Therapeutics (CTMX) Lowered to "Buy" at BidaskClub
www.americanbankingnews.com - March 30 at 1:06 PM |
| $19.77 Million in Sales Expected for CytomX Therapeutics Inc (CTMX) This Quarter
www.americanbankingnews.com - March 29 at 4:36 AM |
| Frederick W. Gluck Sells 5,000 Shares of CytomX Therapeutics Inc (CTMX) Stock
www.americanbankingnews.com - March 27 at 10:35 PM |
| CytomX Therapeutics (CTMX) Upgraded at BidaskClub
www.americanbankingnews.com - March 25 at 9:30 AM |
| FY2018 Earnings Forecast for CytomX Therapeutics Inc Issued By Cantor Fitzgerald (CTMX)
www.americanbankingnews.com - March 23 at 10:54 AM |
| CytomX Therapeutics Inc Forecasted to Earn FY2019 Earnings of ($1.66) Per Share (CTMX)
www.americanbankingnews.com - March 22 at 3:16 PM |
| CytomX Therapeutics (CTMX) Given a $40.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - March 18 at 1:46 PM |
| CytomX Therapeutics (CTMX) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - March 12 at 9:54 PM |
| FY2022 Earnings Estimate for CytomX Therapeutics Inc (CTMX) Issued By Oppenheimer
www.americanbankingnews.com - March 12 at 10:02 AM |
| $22.15 Million in Sales Expected for CytomX Therapeutics Inc (CTMX) This Quarter
www.americanbankingnews.com - March 12 at 4:09 AM |
| Wedbush Weighs in on CytomX Therapeutics Inc's Q1 2018 Earnings (CTMX)
www.americanbankingnews.com - March 12 at 2:32 AM |
| CytomX Therapeutics (CTMX) PT Set at $40.00 by Cantor Fitzgerald
www.americanbankingnews.com - March 10 at 9:24 PM |
| Zacks: Analysts Anticipate CytomX Therapeutics Inc (CTMX) Will Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - March 10 at 3:22 PM |
| CytomX Therapeutics Inc Expected to Post FY2022 Earnings of $3.32 Per Share (CTMX)
www.americanbankingnews.com - March 9 at 4:32 PM |
 | Immuno-Oncology Sector Deals Dominate 2017 Life Sciences Deal of the Year Awards
www.bizjournals.com - March 8 at 6:51 PM |
 | CytomX beats by $0.49, beats on revenue
seekingalpha.com - March 8 at 6:51 PM |
| CytomX Therapeutics (CTMX) PT Raised to $40.00 at Bank of America
www.americanbankingnews.com - March 8 at 6:41 PM |
| CytomX Therapeutics (CTMX) PT Raised to $40.00 at Jefferies Group
www.americanbankingnews.com - March 8 at 6:34 PM |
| Analyzing CytomX Therapeutics (CTMX) and Aclaris Therapeutics (ACRS)
www.americanbankingnews.com - March 8 at 9:18 AM |
| CytomX Therapeutics' (CTMX) CEO Sean McCarthy on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 8 at 8:19 AM |
 | CytomX Therapeutics beats Street 4Q forecasts
finance.yahoo.com - March 8 at 8:19 AM |
| CytomX Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 7 at 6:38 PM |
| What Does CytomX Therapeutics Inc’s (NASDAQ:CTMX) Past Performance Indicative Of Its Future?
finance.yahoo.com - March 7 at 6:38 PM |
| CytomX Therapeutics Announces Full-Year 2017 Financial Results and Provides Operational Update
finance.yahoo.com - March 7 at 6:38 PM |
| Schroder Investment Management Group Acquires 52,348 Shares of CytomX Therapeutics Inc (CTMX)
www.americanbankingnews.com - March 6 at 9:48 AM |
| CytomX Therapeutics Inc (CTMX) Insider Rachel Humphrey Sells 16,160 Shares
www.americanbankingnews.com - March 5 at 9:30 PM |
| Insider Selling: CytomX Therapeutics Inc (CTMX) Director Sells 16,181 Shares of Stock
www.americanbankingnews.com - March 5 at 9:30 PM |
| CytomX Therapeutics Inc (CTMX) CFO Debanjan Ray Sells 33,000 Shares
www.americanbankingnews.com - March 5 at 6:40 PM |
| CytomX Therapeutics Inc (CTMX) Stake Raised by Bogle Investment Management L P DE
www.americanbankingnews.com - March 4 at 4:58 AM |
| CytomX Therapeutics Inc (CTMX) Director Sells $114,570.00 in Stock
www.americanbankingnews.com - March 2 at 12:14 PM |
| Rachel Humphrey Sells 23,840 Shares of CytomX Therapeutics Inc (CTMX) Stock
www.americanbankingnews.com - March 2 at 12:14 PM |
| CytomX to Present at Upcoming Investor Conferences
finance.yahoo.com - March 1 at 5:54 PM |
| CytomX Therapeutics (CTMX) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 28 at 3:32 AM |
 | CytomX Therapeutics to Announce Full-Year 2017 Financial Results and Host Operational Update Webcast ... - GlobeNewswire (press release)
globenewswire.com - February 23 at 8:18 AM |
| $10.70 Million in Sales Expected for CytomX Therapeutics Inc (CTMX) This Quarter
www.americanbankingnews.com - February 23 at 1:06 AM |
| CytomX Therapeutics to Announce Full-Year 2017 Financial Results and Host Operational Update Webcast Conference Call
finance.yahoo.com - February 22 at 5:39 PM |
| CytomX Therapeutics Inc (CTMX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 21 at 7:30 PM |
| CytomX Therapeutics (CTMX) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - February 19 at 9:08 PM |
| Zacks Investment Research Lowers CytomX Therapeutics (CTMX) to Sell
www.americanbankingnews.com - February 12 at 10:12 PM |
| CytomX Therapeutics (CTMX) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - February 5 at 9:16 PM |
| Analysts Anticipate CytomX Therapeutics Inc (CTMX) Will Post Earnings of -$0.39 Per Share
www.americanbankingnews.com - February 4 at 9:06 PM |
| Insider Selling: CytomX Therapeutics Inc (CTMX) CFO Sells 2,548 Shares of Stock
www.americanbankingnews.com - February 2 at 10:02 PM |
CytomX Therapeutics (NASDAQ:CTMX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
CytomX Therapeutics (NASDAQ:CTMX) Income Statement, Balance Sheet and Cash Flow Statement
CytomX Therapeutics (NASDAQ CTMX) Stock Chart for Friday, April, 20, 2018
Loading chart…
